Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280.2 SEK | +0.65% | -2.64% | +4.94% |
May. 14 | Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member | CI |
May. 08 | Sobi Finalizes Inaugural SEK3 Billion Bond Issue | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 4.45 times its current sales, is high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.94% | 8.82B | B+ | ||
-1.62% | 89.22B | A- | ||
+1.32% | 40.49B | A- | ||
-15.73% | 32.79B | B- | ||
+64.13% | 26.23B | A | ||
-21.28% | 14.52B | C | ||
-8.50% | 13.09B | B- | ||
-44.07% | 11.6B | B | ||
-13.06% | 11.5B | D+ | ||
-13.45% | 7.92B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB